AMD 3465
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


AMD 3465
Description :
AMD 3465 (GENZ-644494) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.Product Name Alternative :
GENZ-644494UNSPSC :
12352005Target :
CXCR; HIVType :
Reference compoundRelated Pathways :
Anti-infection; GPCR/G Protein; Immunology/InflammationApplications :
Metabolism-protein/nucleotide metabolismField of Research :
Infection; EndocrinologyAssay Protocol :
https://www.medchemexpress.com/amd-3465.htmlPurity :
99.59Solubility :
H2O : ≥ 100 mg/mLSmiles :
C1(CNCC2=CC=C(CN3CCNCCCNCCNCCC3)C=C2)=NC=CC=C1Molecular Formula :
C24H38N6Molecular Weight :
410.60References & Citations :
[1]Hatse S, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol. 2005 Sep 1;70 (5) :752-61.|[2]Yang L, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007 Jan 15;67 (2) :651-8.Shipping Conditions :
Blue IceStorage Conditions :
-20°C (Powder, protect from light)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedIsoform :
CXCR4; HIV-1; HIV-2Citation 01 :
Br J Haematol. 2023 May;201 (3) :459-469.|Biomed Pharmacother. 2021 Jun:138:111476.|Immunity. 2025 Aug 12:S1074-7613 (25) 00314-0.|J Labelled Comp Radiopharm. 2018 May 15;61 (5) :438-446. |Patent. US20180263995A1.CAS Number :
[185991-24-6]

